Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight
Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight
复制标题
DOI：
10.1007/s00198-012-2243-z
复制
发表时间：
2013-07-01
影响因子：
4
通讯作者：
Ohshima, H.
中科院分区：
文献类型：
--
作者：
LeBlanc, A.;Matsumoto, T.;Ohshima, H.
我们报告了阿仑膦酸钠摄入加运动在防止宇航员在 5.5 个月的太空飞行期间骨量和强度下降以及尿钙和骨吸收水平升高方面的结果。这项研究是 NASA 和 JAXA 航天机构之间的一项国际合作，旨在调查抗骨吸收剂在减轻与长期太空飞行相关的既定骨骼变化方面的潜在价值。我们报告了七名国际空间站 (ISS) 宇航员的结果，他们平均花费了在国际空间站飞行 5.5 个月，从飞行前 3 周开始每周口服 70 毫克阿仑膦酸钠，并在整个任务期间持续服用。所有机组人员都配备了跑步机、自行车测力计和阻力训练装置来锻炼。我们的评估包括使用 X 射线吸收测定法 (DXA) 和定量计算机断层扫描 (QCT) 对多个骨骼区域进行密度测量，以及骨代谢生物标志物测定。除了飞行前和飞行后测量之外，我们还将我们的结果与执行国际空间站任务并使用早期模型阻力运动装置（称为临时阻力运动装置）进行锻炼的 18 名宇航员以及使用较新的先进阻力运动装置进行锻炼的 11 名国际空间站宇航员进行了比较（阿雷德）。我们的研究结果表明，与旧设备相比，ARED 显着减少了骨质流失，尽管飞行后股骨颈和髋部的骨质流失仍然存在。 ARED 和双磷酸盐的组合减弱了太空飞行期间骨生理学改变的几乎所有指标的预期下降，包括：DXA 测定的脊柱、髋部和骨盆的骨矿物质密度损失，QCT 测定的髋部小梁骨和皮质骨量的区室损失，计算的跌倒和站立测量计算的髋部骨强度，骨吸收标志物水平升高以及尿钙排泄。运动与抗反应药物的结合药物可能有助于在长期太空飞行期间保护骨骼健康。
We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight.This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight.We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism.In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium.The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.